Retrieved on:
Wednesday, February 1, 2023
ACT,
Biotechnology,
Monroe Dunaway Anderson,
Anderson,
Genetic distance,
Transplant,
Immunotherapy,
Diagnosis,
Translational research,
Patient,
Clinical trial,
University,
Research,
Surgical oncology,
Bacteria,
MD Anderson Cancer Center,
FMT,
Cancer,
Pharmaceutical industry HOUSTON and SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Federation Bio, a biotechnology company pioneering bacterial cell therapies, today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy. The agreement pairs Federation Bio's proprietary ACT™ (anerobic co-culture technology) platform with the expertise and capabilities of MD Anderson's Platform for Innovative Microbiome and Translational Research (PRIME-TR).
Key Points:
- The agreement pairs Federation Bio's proprietary ACT™ (anerobic co-culture technology) platform with the expertise and capabilities of MD Anderson's Platform for Innovative Microbiome and Translational Research (PRIME-TR).
- Under the agreement, MD Anderson and Federation Bio intend to rationally design a complex consortium of bacteria derived from a donor fecal sample that has a demonstrated ability to improve immunotherapy responses in cancer patients via FMT in a clinical trial.
- Federation Bio currently is evaluating FB-001 in a Phase I clinical trial; it is the first rationally designed complex consortium at this scale to enter clinical studies.
- PRIME-TR is a novel institutional platform that aims to transform the landscape of cancer treatment, diagnosis and prevention through studying and targeting the microbiome at multiple different niches.
Retrieved on:
Tuesday, November 30, 2021
Genentech,
Corcept Therapeutics,
Royal Postgraduate Medical School,
Federation,
Industry,
Nephrology,
Endocrinology,
University of California, San Francisco,
Hammersmith Hospital,
Inflammation,
Amgen,
SAN,
University,
Lists of diseases,
Therapy,
Genetic engineering,
School,
Law,
University Hospital Heidelberg,
Roche,
Biotechnology,
FDA,
Bio,
Pharmaceutical industry,
Medicine SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- Federation Bio , a biotechnology company pioneering engineered bacterial cell therapies, today announced the appointment of two new members to its executive team.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- Federation Bio , a biotechnology company pioneering engineered bacterial cell therapies, today announced the appointment of two new members to its executive team.
- Andreas Grauer, M.D., and Jessie Richardson, J.D., Ph.D.,have joined Federation Bio as chief medical officer and general counsel, respectively.
- "Andreas and Jessie are both recognized industry leaders whose collective expertise perfectly complements that of our existing leadership team," said Emily Drabant Conley, Ph.D., chief executive officer at Federation Bio.
- Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies.
Horizons Ventures led the Series A financing, joined by existing investors Venrock and Altitude, and additional new investors Seventure Partners/Health for Life Capital.
Key Points:
- Horizons Ventures led the Series A financing, joined by existing investors Venrock and Altitude, and additional new investors Seventure Partners/Health for Life Capital.
- "The Federation Bio team has already developed critical platform capabilities and generated strong pre-clinical data.
- "Federation Bio's completely novel approach to microbial therapy creates tremendous potential for a wide range of effective, broadly applicable therapies," said Dr. Conley.
- Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role.
